Uveitis

TRS01 has the potential to be the first-line treatment option for non-infectious uveitis, according to the company.

Nonetheless,BDUMP remains a rare condition with fewer than 60 cases documented in literature.

XIPERE is the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis.

Launched in 2014, Intelligent Research in Sight is the nation's first and largest comprehensive eye disease registry.

This milestone was announced by Clearside Biomedical, Inc., Arctic Vision's partner. ARCATUS, also known as XIPERE®, utilizes a revolutionary suprachoroidal delivery platform, offering new hope to patients in China suffering from this vision-threatening condition.

The week of September 18-24 will be dedicated to educating the public on IEDs such as uveitis, keratitis, conjunctivitis and more.

TRS01 demonstrates clear anti-inflammatory activity in noninfectious anterior uveitis with no evidence of significant adverse effects.

OSC-01 is a novel, high concentration preservative-free topical OPTIREACH formulation of dexamethasone.

The drug, known as XIPERE in the US, is used to treat uvietic macular edema and goes by the name Arcatus when licensed by Clearside Biomedical’s partner in China, Arctic Vision.

This allosteric tyrosine kinase (TYK2) inhibitor may help to treat the disregulation of TYK2 mediated pathways may also play an important role in conditions, including noninfectious uveitis.

The severity and duration of gene therapy–associated uveitis correlated with increasing vector dose.

As a nonsteroid treatment, RG6179 could open new methods for controlling inflammation with fewer adverse effects.

The sale of YUTIQ® will empower EyePoint Pharmaceuticals to continue to advance its pipeline of therapeutics through the company's upcoming clinical trials.

New clinic dedicated to treating pediatric uveitis opens in the UAE.

Research highlights the correlation between the gut microbiome and autoimmune disorders.

An end-of-week review of retina news and stories from October 29-November 3, 2022.

This method of administration facilitates targeted delivery of the medication to the retina and choroid.

Researchers at the University of Bonn are evaluating a new imaging technique for the diagnosis of posterior uveitis.

Survey respondents point to a perceived gap in treatments for uveitic macular edema, document interest in suprachoroidal drug delivery.

The U.S. Centers for Medicare and Medicaid Services code is effective July 1 and will enhance access to Xipere, the only therapy available in the United States for suprachoroidal use in the treatment of macular edema associated with uveitis.

Thomas Albini MD reviews the case of a 54-year-old male with chronic non-infectious uveitis.

A uveitis specialist discusses impressions and key take away points from patient case.

Dr. Thomas Albini MD reviews the case of a 62-year-old male with uveitis.

Modern Retina™ Case-Based Roundtables create an environment for ophthalmology’s brightest minds to examine complex, real-world patient cases in a discussion-based setting. Led by an expert in the topic, the group dissects the case together to improve their knowledge of rare diseases and niche diagnoses. In Fort Lauderdale, Florida, Modern Retina™ hosted Uveitis Case-Based Roundtables. Moderators Thomas Albini, MD, and Eduardo Uchiyama, MD, are uveitis specialists who have encountered intriguing cases in the clinic. Attendees asked questions and reviewed imaging of the cases in hopes of improving their overall patient care. Roundtable 1, led by Dr. Albini and discussed here, investigates two intriguing cases.

Yasha S. Modi, MD, discusses his best tips and tricks for finding and diagnosing infectious uveitis.

Results from our recent poll regarding Retina World Congress 2022 attendance indicate that while many retina specialists will attend the Congress, the majority will not be in Fort Lauderdale, Florida.

The Phase 3 integrated PEACHTREE and AZALEA study data revealed strong safety and efficacy for triamcinolone acetonide via suprachoirodal injection.

Investigators from the Karolinska Institutet and St. Erik Eye Hospital, Stockholm, Sweden, reported that they have developed a prognostic test, referred to as serUM, that they believe is a strong predictor of metastasis of uveal melanoma.

A poll for retina specialists regarding their attendance at the 2022 Retina World Congress in Fort Lauderdale, Florida. This poll is now closed.